Header Logo

Connection

Ian Sanne to Drug Administration Schedule

This is a "connection" page, showing publications Ian Sanne has written about Drug Administration Schedule.
Connection Strength

0,588
  1. Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open. 2017 06 10; 7(6):e015620.
    View in: PubMed
    Score: 0,138
  2. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
    View in: PubMed
    Score: 0,078
  3. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
    View in: PubMed
    Score: 0,045
  4. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. Lancet Glob Health. 2021 05; 9(5):e628-e638.
    View in: PubMed
    Score: 0,045
  5. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
    View in: PubMed
    Score: 0,038
  6. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017 01; 17(1):39-49.
    View in: PubMed
    Score: 0,033
  7. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.
    View in: PubMed
    Score: 0,028
  8. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
    View in: PubMed
    Score: 0,027
  9. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
    View in: PubMed
    Score: 0,025
  10. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
    View in: PubMed
    Score: 0,023
  11. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
    View in: PubMed
    Score: 0,022
  12. Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
    View in: PubMed
    Score: 0,022
  13. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
    View in: PubMed
    Score: 0,022
  14. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 01; 50(7):1041-52.
    View in: PubMed
    Score: 0,021
  15. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4(5):e5575.
    View in: PubMed
    Score: 0,020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.